病毒学抑制的HIV-1感染成人中使用低剂量利托那韦增效达芦那韦:一项开放标签试验(ANRS 165 Darulight)
这项多中心、II期、非比较性、单臂、开放标签研究在法国三级医院纳入100例病毒学抑制的HIV-1感染成人,将每日一次达芦那韦/利托那韦(800/100 mg)联合两种NRTI方案转换为达芦那韦/利托那韦(400/100 mg)联合相同NRTI。改良意向治疗分析显示48周治疗成功率为91.6%(87/95;95%CI 84.1%-96.3%),3例可扩增基因型中未检测到耐药相关突变,64例患者发生212例不良事件,其中9例为严重不良事件,无因不良事件停药。
要点
- 病毒学抑制患者将达芦那韦/利托那韦从800/100 mg减至400/100 mg联合两种NRTI,48周治疗成功率91.6%(87/95;95%CI 84.1%-96.3%)。
- 3例可扩增基因型中未检测到达芦那韦或NRTI耐药相关突变。
- 64例患者发生212例不良事件,9例为严重不良事件,无因不良事件停药。
核心结论
- 在达芦那韦/利托那韦(800/100 mg)联合两种NRTI良好抑制的HIV感染患者中,将达芦那韦剂量降至400 mg/日可维持病毒学疗效,且48周内安全。
研究设计与样本
- 多中心、II期、非比较性、单臂、开放标签研究,在法国三级医院开展。
- 纳入100例HIV-1感染成人,无达芦那韦或NRTI耐药相关突变,且每日一次达芦那韦/利托那韦(800/100 mg)联合两种NRTI方案下血浆HIV RNA≤50 copies/mL持续≥12个月、联合两种NRTI≥6个月。
- 转换为达芦那韦/利托那韦400/100 mg联合相同两种NRTI,主要结局为改良意向治疗分析中48周内血浆HIV RNA≤50 copies/mL且研究方案未改变的患者比例。
主要发现
- 基线时多数患者为男性(78%),中位年龄43岁,HIV RNA≤50 copies/mL中位持续35个月,中位CD4 T细胞计数633 cells/mm3。
- 76%患者接受替诺福韦/恩曲他滨,24%接受阿巴卡韦/拉米夫定。
- 5例患者被排除出改良意向治疗分析。
- 至第48周治疗成功率为91.6%(87/95;95%CI 84.1%-96.3%)。
- 3例可扩增基因型中未检测到耐药相关突变;64例患者发生212例不良事件(64%),9例为严重不良事件,无导致停药者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess whether low-dose ritonavir-boosted darunavir (darunavir/r) in combination with two NRTIs could maintain virological suppression in patients on a standard regimen of darunavir/r + two NRTIs. DESIGN: A multicentre, Phase II, non-comparative, single-arm, open-label study. SETTING: Tertiary care hospitals in France. SUBJECTS: One hundred HIV-1-infected adults with no darunavir or NRTI resistance-associated mutations (RAMs) and a plasma HIV RNA level ≤50 copies/mL for ≥12 months on once-daily darunavir/r (800/100 mg) + two NRTIs for ≥6 months were switched to darunavir/r 400/100 mg with the same NRTIs. PRIMARY OUTCOME MEASURE: Proportion of patients with treatment success: plasma HIV RNA level ≤50 copies/mL up to 48 weeks without any change in the study regimen, in a modified ITT (mITT) analysis. RESULTS: At baseline, most patients were male (78%), with a median age of 43 years, median duration of HIV RNA ≤50 copies/mL of 35 months and median CD4 T cell count of 633 cells/mm3. Seventy-six percent received tenofovir/emtricitabine and 24% abacavir/lamivudine. Five patients were excluded from the mITT analysis. The rate of treatment success through to week 48 was 91.6% (87/95; 95% CI 84.1%-96.3%). No RAM was detected in three amplifiable genotypes. A total of 212 adverse events (AEs) occurred in 64 patients (64%); 9 AEs were serious, none leading to treatment discontinuation. CONCLUSIONS: In HIV-infected patients well suppressed with darunavir/r (800/100 mg) and two NRTIs, a reduction of the darunavir dose to 400 mg/day maintained virological efficacy and was safe over 48 weeks.
引用
- Molina JM, Gallien S, Chaix ML, et al. Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight). J Antimicrob Chemother. 2018. PMID: 29860402. doi:10.1093/jac/dky181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。